安罗替尼联合治疗在HER-2阴性晚期乳腺癌的临床观察
Clinical observation of combined treatment of antirotinib in HER-2 negative advanced breast cancer
熊伟力 1许婷 1张莉莉 1袁渊2
作者信息
- 1. 210009 南京 南京医科大学附属肿瘤医院 江苏省肿瘤医院肿瘤内科
- 2. 210009 江苏省肿瘤医院肿瘤内科
- 折叠
摘要
目的 观察安罗替尼联合治疗在人表皮生长因子受体-2(HER-2)阴性晚期乳腺癌患者的疗效和安全性.方法 收集 2019 年 10 月18 日至2023 年7 月15 日在江苏省肿瘤医院予安罗替尼联合治疗方案的HER-2阴性晚期乳腺癌患者的临床病历资料.采用RECIST 1.1 版标准评价疗效,采用CTCAE 5.0 版标准评价不良反应.采用Kaplan-Meier法绘制生存曲线,生存差异行Log-rank 检验.结果 共纳入 85 例患者,中位随访时间为 8.7 个月(1.6～41.8 个月),中位无进展生存时间(PFS)为 7.4 个月(95%CI:6.5～9.0 个月),ORR、DCR、CBR分别为 37.6%、85.9%和 52.9%.激素受体阳性和三阴性乳腺癌患者的中位PFS分别为 6.8 个月(95%CI:5.7～8.9 个月)和 8.7 个月(95%CI:7.0～11.7 个月).治疗线数≤3 线和＞3 线治疗患者的中位PFS未见明显差异[7.6 个月(95%CI:6.8～10.2 个月)vs.6.7 个月(95%CI:5.8～10.2 个月),P=0.531].常见不良反应包括血小板降低(40.0%)、中性粒细胞降低(36.5%)、白细胞降低(36.5%)、贫血(23.5%)和丙氨酸转移酶升高(20.0%).结论 安罗替尼联合治疗在标准治疗失败的HER-2阴性晚期乳腺癌患者中,显示出较好的疗效,且不良反应可控.
Abstract
Objective To observe the efficacy and safety of antirotinib combined therapy in human epidermal growth factor receptor-2(HER-2)negative advanced breast cancer.Methods Clinical medical records of patients with HER2-negative advanced breast cancer who received anrotinib combination therapy in Jiangsu Cancer Hospital from October 18,2019 to July 15,2023 were collected.RECIST 1.1 standard was used to evaluate the efficacy and CTCAE 5.0 standard was used to evaluate the adverse reactions.Survival curve was drawn by Kaplan-Meier method,and survival difference was tested by Log-rank.Results A total of 85 patients were included.The median follow-up time was 8.7 months(1.6-41.8 months),the median progression-free survival time(PFS)was 7.4 months(95%CI:6.5-9.0 months),and the ORR,DCR,and CBR were 37.6%,85.9%,and 52.9%,respectively.The median PFS for patients with hormone receptor-positive and triple-negative breast cancer were 6.8 months(95%CI:5.7 to 8.9 months)and 8.7 months(95%CI:7.0-11.7 months),respectively.There was no significant difference in median PFS between patients treated with≤3 lines and those treated with＞3 lines[7.6 months(95%CI:6.8-10.2 months)vs.6.7 months(95%CI:5.8-10.2 months),P=0.531].The most common adverse reactions included thrombocytopenia(40.0%),neutropenia(36.5%),leukopenia(36.5%),anemia(23.5%)and elevated alanine transferase(20.0%).Conclusion The combined treatment of anrotinib showed good efficacy and controllable adverse reactions in patients with HER-2 negative advanced breast cancer who failed standard treatment.
关键词
晚期乳腺癌/安罗替尼/HER-2阴性/疗效/不良反应Key words
Metastatic breast cancer/Anlotinib/HER-2 negative/Efficacy/Side effects引用本文复制引用
出版年
2024
NETL
NSTL
万方数据